Study: Income, BMI linked to CCE completion
-
February 19
Danish screening data identify clinical and socioeconomic factors that significantly influence the likelihood of a complete colon capsule examination.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
With a little help from my friends: What gastrointestinal pathologists need to know from gastroenterologists
-
February 1
-
by Raul S. Gonzalez, MD
Why better communication between gastroenterologists and pathologists matters for patient care.
Green endoscopy: Practical strategies to reduce environmental impact in GI practice
-
February 1
-
by Rabia de Latour, MD
There are plenty of opportunities for gastroenterologists, ambulatory surgery centers, endoscopy units, and outpatient clinics to implement changes that reduce GHG emissions.
The Latest
Study: Income, BMI linked to CCE completion
-
by Doug Brunk
Danish screening data identify clinical and socioeconomic factors that significantly influence the likelihood of a complete colon capsule examination.
Inflammation severity at cancer diagnosis tied to outcomes in ulcerative colitis
-
by Sierra Rendon
Nationwide Japanese study finds colorectal cancers within UC-affected mucosa linked to lower recurrence-free and cancer-specific survival.
Diabetes duration tied to risk of pancreatic cystic neoplasms in nationwide cohort
-
by Amy Pfeiffer
A population-based Korean cohort study found increasing pancreatic cyst risk with worsening glycemic status, with the highest risk among individuals with diabetes for 5 years or longer.
Endoscopic ultrasound pushes beyond biopsy in diagnostics
-
by Doug Brunk
Review highlights advances that expand endoscopic ultrasound into precision diagnostics and personalized therapy across pancreatic and liver diseases.
Advances in Crohn’s disease therapies show similar safety
-
by Doug Brunk
Large claims analysis finds no significant differences in serious infections, VTE, or MACE across biologics and JAK inhibitors.
